MTSS1 and acute myeloid leukemia: Supporting a contribution of MTSS1 downregulation to chemotherapy resistance in AML, both CRISPR/ CRISPR-associated 9 (Cas9)-mediated knockout and shRNA-mediated knockdown of MTSS1 in three different human myeloid cell lines increased their resistance to araC and daunorubicin, possibly via an increased DNA damage response [94].